UBI Pharma signs an investment and exclusive licensing sales agreement with Ory Biotech Co., Ltd. for the bio-similar drug UB-851.

Our company has signed an investment and exclusive licensing sales agreement with Ory Biotech Co., Ltd. for the bio-similar drug UB-851. This agreement grants Ory Biotech Co., Ltd. the exclusive rights to commercialize UB-851 for the treatment of renal anemia in 11 Muslim countries. Through this collaboration, we aim to expand our market size and product sales, contributing to the development of our business and the expansion of our market reach.

UB-851 (Recombinant Human Erythropoietin): Erythropoietin (EPO) is a glycoprotein cytokine produced by interstitial fibroblasts in the renal cortex, which regulates the production of red blood cells in the body by promoting the differentiation of precursor cells into erythrocytes in the bone marrow. Recombinant human erythropoietin is produced using genetic engineering technology through cell culture to generate synthetic erythropoietin. UBI Pharma's UB-851 is developed according to the specifications of the European Pharmacopoeia and reference drugs, and its protein structure and efficacy in animal and human trials have been confirmed to be similar to the reference drug. The final product has passed strict quality control inspections and analyses.

The global human erythropoietin drug market was valued at $6.87 billion in 2022, with a projected compound annual growth rate (CAGR) from 2023 to 2030 of 1.5%.